Literature DB >> 25092015

Capsule commentary on Piller et al., Characteristics and long-term follow-up of participants with peripheral vascular disease during ALLHAT.

Stephen K Williams1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25092015      PMCID： PMC4238190          DOI： 10.1007/s11606-014-2983-x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  4 in total

1.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

2.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

3.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

4.  Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.

Authors:  Linda B Piller; Lara M Simpson; Sarah Baraniuk; Gabriel B Habib; Mahboob Rahman; Jan N Basile; Richard A Dart; Allan J Ellsworth; Herbert Fendley; Jeffrey L Probstfield; Paul K Whelton; Barry R Davis
Journal:  J Gen Intern Med       Date:  2014-11       Impact factor: 5.128
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.